Introduction {#S1}
============

HSCs are maintained by their microenvironmental niches. Recently, we identified bone marrow *Lepr*^+^ mesenchymal stromal cells as a critical component of the niche that elaborates multiple factors, including stem cell factor (SCF) and CXCL12 ^[@R1],\ [@R2]^. These stromal cells include skeletal stem cells that are the main source of bone in the adult bone marrow ^[@R3]^. Although our understanding of the mesenchymal stromal cells under steady state has advanced quickly, how these cells are altered by and contribute to haematological diseases has not been well characterized ^[@R4]^.

PMF is a subtype of myeloproliferative neoplasms (MPNs) with clinical characteristics, including anemia, bone marrow fibrosis and extramedullary haematopoiesis ^[@R5]^. Most PMF patients are elderly. PMF originates clonally from abnormal haematopoietic stem/progenitor cells. Allogeneic HSC transplantation is the only possible cure. However, this approach is too toxic for elderly people, precluding its application to most PMF patients. The haematopoietic-intrinsic molecular mechanisms that lead to PMF have been studied extensively ^[@R6]^. Several driver mutations have been identified, including JAK2V617F and MPLW515L mutations that lead to constitutive activation of JAK2 kinase and the upstream receptor MPL, respectively ^[@R6]^. Calreticulin mutations that activate the MPL receptor ^[@R7]-[@R9]^ have recently been discovered in most JAK2/MPL mutation-negative patients ^[@R10],\ [@R11]^. Thus, activation of the MPL-JAK-STAT pathway in haematopoietic cells is a general feature of MPNs, regardless of the specific molecular mechanisms. Consistent with this, a comprehensive genomic analysis has identified gene signature of JAK-STAT activation in all MPN patients, independent of mutations ^[@R12]^. Currently, JAK inhibitors have been actively explored as a means to treat PMF. While these inhibitors control symptoms, they do not resolve the disease, particularly the bone marrow fibrosis ^[@R6]^. Thus a deeper understanding of the fibrotic component of PMF pathogenesis is required to devise more effective therapies.

The cellular mechanisms underlying bone marrow fibrosis are still being elucidated. An earlier study of X chromosome-linked markers in a female PMF patient revealed that haematopoietic cell overproliferation was clonal while the bone marrow fibrosis was not ^[@R13]^. Mouse models with MPN-associated mutations have demonstrated that MPNs originate from abnormal haematopoietic clones ^[@R14]^. But how overproliferating haematopoietic cells lead to bone marrow fibrosis and extramedullary haematopoiesis is not clear. Megakaryocyte deregulation and hyperplasia is a defining cellular feature of PMF ^[@R6],\ [@R15]^. Overexpression of the major megakaryopoietic cytokine, thrombopoietin (TPO), leads to megakaryocyte hyperplasia and PMF in mice ^[@R16],\ [@R17]^. Gata1^low^ mice with a block in megakaryocyte maturation ^[@R18]^. developed myelofibrosis, suggesting a disease model where dysregulated megakaryocytes secrete excessive cytokines, including transforming growth factor-beta 1 (Tgfβ1) and platelet-derived growth factor (PDGF) that drive bone marrow fibrosis ^[@R19]^. Indeed, targeting deregulated megakaryocytes by inhibiting the AURKA pathway eliminated bone marrow fibrosis ^[@R20]^. However, the bone marrow stromal cells that respond to the cytokines elaborated by hyperplastic megakaryocytes and that directly deposit reticulin and collagen fibers have not been identified.

PDGFs are potent cytokines that promote mesenchymal cell proliferation and are implicated in many fibrotic diseases, including pulmonary and liver fibrosis ^[@R21]^. Activation of PDGFRa signaling is sufficient to drive fibrosis in diverse organs ^[@R22],\ [@R23]^. PMF patients have significantly higher concentrations of PDGFs in circulation, likely due to increased release ^[@R24]^. However, whether PDGFR pathways play a role in bone marrow fibrosis has not been directly addressed.

It has been speculated that cells of the fibroblastic lineage are the origin of myofibroblasts in PMF ^[@R5],\ [@R25]^. A number of markers have been used to identify mouse bone marrow fibroblastic stromal cells, also referred to as colony-forming unit-fibroblast (CFU-F), including Nestin-GFP, CD51, PDGFRa, PDGFRb and NG2 ^[@R26]-[@R30]^. Using some of these markers, several studies characterized the mesenchymal stromal cells in MPN mouse models. In a chronic myeloid leukemia (CML) model, Schepers *et al* reported an expansion of Lin^−^CD45^−^CD31^−^CD51^+^Sca1^−^ osteoblastic lineage cells and increase collagen deposition. However, it was not clear whether these cells were the origin of bone marrow fibrosis ^[@R31]^. In a Jak2^V617F^ MPN model, Arranz *et al* performed lineage-tracing using *Nestin*-creER to assess the contribution of Nestin^+^ stromal cells. No obvious contribution of these cells to bone marrow fibrosis was noted ^[@R32]^. As a result, the stromal cells that directly contribute to bone marrow fibrosis are unknown. Given the central role of PDGFR signaling in myofibroblasts and fibrosis, we searched for bone marrow stromal cells that express PDGFRs. Previously, we reported that *Lepr^+^* stromal cells are uniformly positive for PDGFRa and PDGFRb ^[@R1],\ [@R3]^. Conversely, virtually all PDGFR^+^ stromal cells in the bone marrow are *Lepr^+^* ^[@R3]^. This raises the question of whether the Lepr^+^PDGFR^+^ stromal cells are the origin of myofibroblasts in PMF.

We set out to identify the stromal cells that generate reticulin and collagen fiber in myelofibrosis using lineage tracing. We found that *Lepr^+^* mesenchymal stromal cells were the source of myofibroblasts and underwent expansion in PMF. These cells down-regulated key HSC maintenance factors and up-regulated fibrogenic and osteogenic genes. Conditional deletion of *Pdgfra* from *Lepr^+^* mesenchymal stromal cells or administrating imatinib suppressed their expansion and largely abolished bone marrow fibrosis. Conversely, activation of PDGFRa pathway in *Lepr^+^* mesenchymal stromal cells led to their expansion and extramedullary haematopoiesis. Our results identify the activation of the PDGFRa pathway in *Lepr^+^* cells as an important contributor to myelofibrosis and provide a proof of principle that inhibiting the PDGFRa pathway in mesenchymal stromal cells is an attractive strategy to treat bone marrow fibrosis.

Results {#S2}
=======

Development of primary myelofibrosis in *Tpo*-overexpressing mice {#S3}
-----------------------------------------------------------------

We adapted a retroviral mouse PMF model by transplanting *Tpo*-overexpressing (TOE) retrovirally-infected bone marrow cells into irradiated mice. Consistent with prior reports ^[@R16],\ [@R17]^, these mice developed high levels of serum TPO ([Fig. 1a](#F1){ref-type="fig"}), thrombocythemia ([Fig. 1b](#F1){ref-type="fig"}) and a trend towards leukocytosis ([Fig. 1c](#F1){ref-type="fig"}) within three months after the transplantation. The bone marrow from the TOE mice was pale, particularly in mice with advanced PMF ([Fig. 1d](#F1){ref-type="fig"}). Enlarged spleens with extramedullary haematopoiesis were evident accompanied by a 3-fold increase in spleen weight ([Fig. 1e and f](#F1){ref-type="fig"}). Bone marrow myeloid cells significantly expanded in TOE mice (58±13% cells were myeloid cells in TOE vs 40±8% in controls) ([Fig. 1g](#F1){ref-type="fig"}). These mice displayed megakaryocyte hyperplasia in the bone marrow ([Fig. 1h](#F1){ref-type="fig"}) and profound fibrosis in the spleen and bone marrow ([Fig. 1i and j](#F1){ref-type="fig"}). Large amounts of collagen fibers and osteosclerosis associated with fibrosis made dissociation of bone marrow cells from TOE mice into single cell suspension difficult. These observations indicate that the TOE model developed features of PMF as previously reported ^[@R16],\ [@R17]^.

HSCs undergo proliferation and mobilization in TOE mice {#S4}
-------------------------------------------------------

We examined HSC and progenitor compartments in TOE mice 2--4 months after the bone marrow transplantation. There was a 5-fold increase of the frequency of Lin^−^Sca1^+^cKit^+^CD150^+^CD48^−^ HSCs in the bone marrow of TOE mice compared with mice transplanted with control virus-infected bone marrow cells ([Fig. 2a and b](#F2){ref-type="fig"}). Similarly, Lin^−^Sca1^+^cKit^+^CD150^−^CD48^−^ multipotent progenitors (MPPs) and Lin^−^Sca1^+^cKit^+^ haematopoietic progenitors (HPCs) were also significantly increased ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). Bone marrow cellularity was significantly reduced in TOE mice ([Fig. 2c](#F2){ref-type="fig"}). An overall quantification revealed an increased of HSC number in TOE bone marrow ([Fig. 2d](#F2){ref-type="fig"}). There were variations among the TOE mice in term of haematopoietic phenotypes presumably due to variable amount of TPO (thus variable fibrosis induction strength) in individual mice. When the mice were grouped into intermediate and advanced stages based on their haematopoietic parameters (e.g. color of the bone marrow and ease of bone marrow dissociation), we observed an initial significant increase of bone marrow HSC number in intermediate followed by a reduction of HSCs in advanced PMF mice ([Fig. 2e](#F2){ref-type="fig"}), consistent with clinical data on different stages of PMF patients ^[@R33]^. MPPs and HPCs showed similar alterations ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). This is associated with a gradual depletion of bone marrow cellularity ([Fig. 2f](#F2){ref-type="fig"}). HSCs from TOE mice incorporated more BrdU in 5-day pulse experiments ([Fig. 2g](#F2){ref-type="fig"} and [Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}), suggesting they proliferated more.

There was a 1.6-fold more of mechanically dissociable cells in the spleens from TOE mice ([Fig. 2h](#F2){ref-type="fig"}). This was probably an underestimate because dissociation of TOE spleens was difficult due to extensive fibrosis. HSC frequency and number increased significantly in the TOE spleens ([Fig. 2i and j](#F2){ref-type="fig"}). HSCs shifted from the bone marrow to the spleen in advanced PMF mice ([Fig. 2k](#F2){ref-type="fig"} and [Supplementary Fig. 1c--f](#SD1){ref-type="supplementary-material"}). Overall, total HSC number first increased in intermediate PMF followed by a reduction in advanced PMF ([Supplementary Fig. 1g](#SD1){ref-type="supplementary-material"}). These data suggest a pathogenic process of PMF: HSCs initially overproliferate and start mobilizing to the spleen; as the disease progresses, the bone marrow becomes fibrotic and hypocellular, and many HSCs shift to the spleen in advanced stages of PMF.

*Lepr^+^* mesenchymal stromal cells undergo fibrotic expansion {#S5}
--------------------------------------------------------------

The above data suggest that bone marrow fibrosis contributes to bone marrow haematopoietic failure. However, the identity of cells that deposit collagen fibers and render bone marrow fibrotic is elusive. Bone marrow *Lepr^+^* mesenchymal stromal cells, which uniformly express PDGFRa and PDGFRb ^[@R1],\ [@R3]^, arise perinatally and are major contributor to bone formed in adults but not during development ^[@R3]^. They give rise to nearly all CFU-Fs in adult bone marrow and can differentiate into bone, cartilage and adipocytes *in vitro* and *in vivo* ^[@R3]^. These observations prompted us to test whether *Lepr^+^* stromal cells are responsible for bone marrow fibrosis *in vivo*. The frequency of enzymatically dissociated CD45/Ter119^−^PDGFRa^+^ stromal cells significantly increased in TOE mice ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). *Lepr-cre* knockin allele recombines specifically in PDGFRa^+^ bone marrow mesenchymal stromal cells^[@R1],\ [@R3]^. We fate-mapped *Lepr^+^* lineage cells using *Lepr-cre; tdTomato* mice in which PMF was induced by transplanting TOE retrovirus-infected bone marrow cells ([Fig. 3b](#F3){ref-type="fig"}). Consistent with the increased stromal cell frequency ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}), tdTomato^+^ cells expanded dramatically in TOE mice compared with mice transplanted with bone marrow cells infected with control virus ([Fig. 3c--f](#F3){ref-type="fig"} and [Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). These tdTomato^+^ stromal lineage cells elaborated extensive cellular processes resembling myofibroblasts ([Fig. 3e and f](#F3){ref-type="fig"} and [Supplementary Fig. 2c--d](#SD1){ref-type="supplementary-material"}), suggesting that these cells assumed a fibrotic cell fate.

To directly assess whether the *Lepr^+^* stromal cells are the myofibroblastic cells, we used *Collagen1a1-*GFP (Col-GFP) reporter mice ^[@R34]^, which labels Collagen1a1-expressing myofibroblastic cells in multiple organs ^[@R23],\ [@R35],\ [@R36]^. We generated *Lepr-cre; tdTomato; Col-gfp* mice to examine whether tdTomato^+^ cells are Col-GFP^+^ in the PMF bone marrow. In *Lepr-cre; tdTomato; Col-gfp* mice without PMF induction, sparse tdTomato^+^ cells and Col-GFP^+^ cells overlapped ([Fig. 3g--i](#F3){ref-type="fig"}), suggesting that *Lepr*^+^ stromal cells expressed collagen and had some fibrogenic capacity even under steady state. We then induced PMF by transplanting TOE virus-infected bone marrow cells into these mice. At three to four months after the transplantation, mice were analyzed. Consistent with our earlier observation, tdTomato^+^ stromal lineage cells underwent a significant expansion in TOE bone marrow ([Fig. 3j--o](#F3){ref-type="fig"}). Virtually all of the tdTomato^+^ cells were Col-GFP^+^ ([Fig. 3j--o](#F3){ref-type="fig"} and [Supplementary Fig. 2e](#SD1){ref-type="supplementary-material"}). Conversely, virtually all Col-GFP^+^ cells were tdTomato^+^ ([Fig. 3j--o](#F3){ref-type="fig"} and [Supplementary Fig. 2f](#SD1){ref-type="supplementary-material"}). These data demonstrate that *Lepr*^+^ lineage cells are the major if not exclusive source of myofibroblasts responsible for fibrosis in the PMF bone marrow.

Mesenchymal stromal cells down-regulate key niche factors for HSCs {#S6}
------------------------------------------------------------------

*Lepr^+^* mesenchymal stromal cells plays a critical role in bone marrow HSC maintenance by generating key niche factors, CXCL12 and SCF ^[@R1],\ [@R2],\ [@R37]^. Bone marrow *Lepr^+^* cells, *Cxcl12^high^* cells and *Scf^high^* cells are essentially the same mesenchymal population ^[@R1]-[@R3]^. Fibrogenic conversion of these cells may alter their capacity to support HSCs. We examined the niche function of these cells in PMF by evaluating the expression of key niche-derived HSC maintenance factors. We directly assessed CXCL12 expression in the bone marrow from *Cxcl12^DsRed/+^* knockin mice ^[@R2]^ with PMF induction. *Cxcl12^DsRed/+^* mice reconstituted with empty vector virus-infected bone marrow cells were used as controls. The expression level of *Cxcl12*-DsRed was reduced in TOE mice compared with controls, although the frequency of these cells did not seem to change as revealed by confocal microscopy ([Fig. 4a--d](#F4){ref-type="fig"} and [Supplementary Fig. 3a--d](#SD1){ref-type="supplementary-material"}) and by flow cytometry ([Fig. 4e](#F4){ref-type="fig"}). Quantification of the intensity of *Cxcl12*-DsRed and quantitative real-time PCR (qRT-PCR) analysis showed that there was significant reduction of DsRed expression level and *Cxcl12* transcripts by mesenchymal stromal cells ([Fig. 4f--h](#F4){ref-type="fig"} and [Supplementary Fig. 3e](#SD1){ref-type="supplementary-material"}). Many of the *Cxcl12*-DsRed^+^ stromal cells displayed elongated fibroblast-like cell morphology ([Supplementary Fig. 3c and d](#SD1){ref-type="supplementary-material"}), consistent with the notion that these cells adopted a fibrogenic cell fate. Since CXCL12 is a major HSC retention signal ^[@R2],\ [@R38]^, its down-regulation provides a potential mechanistic explanation for HSC mobilization out of the bone marrow in PMF.

Taking advantage of an *Scf^gfp/+^* knockin reporter ^[@R1]^, we assessed the expression of *Scf*-GFP^+^ in the PMF bone marrow. There was a down-regulation of *Scf*-GFP expression level in the PMF bone marrow revealed by confocal microscopy ([Fig. 4i--l](#F4){ref-type="fig"}). By flow cytometry, the frequency of CD45/Ter119^−^*Scf-*GFP^+^ stromal cells did not differ significantly between TOE and control bone marrow ([Fig. 4m](#F4){ref-type="fig"} and [Supplementary Fig. 3f](#SD1){ref-type="supplementary-material"}). The *Scf*-GFP expression level at single-cell resolution was significantly reduced in PMF bone marrow as assessed by flow cytometry ([Fig. 4n and o](#F4){ref-type="fig"}). qRT-PCR analysis also showed a significant reduction of *Scf* transcripts ([Fig. 4p](#F4){ref-type="fig"} and [Supplementary Fig. 3e](#SD1){ref-type="supplementary-material"}). Overall, the above data suggest that adaptation of a fibrotic cell fate by mesenchymal stromal cells leads to lower expression of key HSC niche factors and thus compromised bone marrow niche.

Mesenchymal stromal cells undergo fibrotic conversion/differentiation in PMF {#S7}
----------------------------------------------------------------------------

We performed a genome-wide gene expression profiling to molecularly characterize the mesenchymal stromal cells in PMF. We sorted CD45/Ter119^−^*Cxcl12*-DsRed^+^ mesenchymal stromal cells as *Cxcl12* expression is a direct marker for functional HSC niche cells. Although *Cxcl12*-DsRed is expressed by other bone marrow cells at low levels ^[@R2]^ and its expression level was down-regulated \~ 4 fold ([Fig. 4f and g](#F4){ref-type="fig"}), our sorting strategy purified most mesenchymal stromal cells expressing high levels of DsRed ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). As expected, these cells also expressed high levels of mesenchymal markers such as *Pdgfra (CD140a), Pdgfrb(CD140b)* and *Lepr* ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}). CD45/Ter119^−^*Cxcl12*-DsRed^+^ cells expressed very little, if any, *Nestin* or *Ng2* ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}). Statistical analysis identified 480 up-regulated genes (p\<0.05, fold\>1.5) and 146 down-regulated genes (p\<0.05, fold\>1.5) from TOE mice compared with controls ([Fig. 5a](#F5){ref-type="fig"}). Gene ontology (GO) analysis using the Database for Annotation, Visualization and Integrated Discovery (DAVID) identified several significantly enriched processes, including extracellular matrix, cell adhesion and proteinaceous extracellular matrix ([Fig. 5b](#F5){ref-type="fig"}), suggesting a fibrotic conversion/differentiation of these cells.

To systematically test whether these cells underwent fibrotic conversion, we performed gene set enrichment analysis (GSEA). A mouse fibrosis gene set was obtained from Qiagen ([www.qiagen.com](www.qiagen.com)), which includes 85 key genes involved in dysregulated tissue remodeling during the repair and healing of wounds ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}). We found that *Cxcl12^+^* mesenchymal stromal cells from PMF bone marrow expressed many genes associated with fibrosis (normalized enrichment score (NES)=3.32, false discovery rate (FDR) q=0 and p=0) ([Fig. 5c](#F5){ref-type="fig"}). Using a published fibrosis gene signature from *in vivo* fibrotic liver stellate cells ^[@R39]^, we performed an independent GSEA analysis. Again, PMF mesenchymal stromal cells significantly expressed many genes associated with liver stellate cell fibrosis (NES=1.65, FDR q=0 and p=0), confirming their fibrotic conversion ([Fig. 5d](#F5){ref-type="fig"}). Since *Lepr^+^* stromal cells are the main source of bone formed in the adult bone marrow ^[@R3]^ and osteosclerosis is a feature of myelofibrosis ^[@R40]^, we tested whether the PMF mesenchymal stromal cells globally up-regulated osteoblastic genes. A mouse osteogenesis gene set was obtained from Qiagen ([www.qiagen.com](www.qiagen.com)), which includes 82 genes related to osteogenic differentiation ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}). A GSEA analysis revealed that PMF mesenchymal stromal cells significantly expressed many osteogenic genes (NES=1.7, FDR q=0 and p=0) ([Fig. 5e](#F5){ref-type="fig"}). Thus the mesenchymal stromal cells underwent global gene expression change to a fibrotic/osteogenic fate in the PMF bone marrow.

Genes that were significantly more highly expressed in PMF mesenchymal stromal cells included genes encoding extracellular matrix: *Acta2* (a-smooth muscle actin), *Fn* (fibronectin), several collagens (*Col12a1*, *Col1a1*, *Col1a2* and *Col3a1*) and integrins (*Itgbl1*, *Itga2* and *Itgb5*) ([Supplementary Table 1](#SD8){ref-type="supplementary-material"}). Extracellular matrix remodeling enzymes were also up-regulated, including *Mmp9* (matrix metallopeptidase 9), *Timp1* (tissue inhibitor of metalloproteinase 1), *Mmp2* (matrix metallopeptidase 2), *Timp3* (tissue inhibitor of metalloproteinase 3) and *Mmp14* (matrix metallopeptidase 14) ([Supplementary Table 1](#SD8){ref-type="supplementary-material"}). Several highly up-regulated genes associated with osteogenesis included *Postn* (periostin, osteoblast specific factor), *Spp1* (secreted phosphoprotein 1, osteopontin) and *Alpl* (alkaline phosphatase, liver/bone/kidney) ([Supplementary Table 1](#SD8){ref-type="supplementary-material"}). We also observed a significant reduction of *Lepr* ([Supplementary Table 1](#SD8){ref-type="supplementary-material"}), although the expression level was still high ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}). A recent study reported that LepR from bone marrow stromal cells promotes adipogenesis and inhibits osteogenesis ^[@R41]^. The down-regulation of *Lepr* is consistent with the elevated osteogenesis of these cells in PMF. In line with our analysis on niche factor expression ([Figure 4](#F4){ref-type="fig"}), we also observed downregulation of *Cxcl12* and *Scf* ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}). Altogether, these data demonstrate that bone marrow mesenchymal stromal cells undergo fibrotic conversion/differentiation and are thus likely the origin of myofibroblasts responsible for fibrosis in the PMF bone marrow.

PDGFRa in mesenchymal stromal cells is required for bone marrow fibrosis {#S8}
------------------------------------------------------------------------

The identification of *Lepr^+^* mesenchymal stromal lineage cells as bone marrow myofibroblasts in PMF provided us an opportunity to investigate the molecular pathways involved in their fibrotic conversion. Activation of PDGFRa has been implicated in fibrosis of multiple organs ^[@R22],\ [@R23]^. As *Lepr^+^* mesenchymal stromal cells are the major cell type expressing PDGFRa in the bone marrow ^[@R1]^, we wondered whether PDGFRa in mesenchymal stromal cells is required for their fibrotic conversion. We conditionally deleted *Pdgfra* from bone marrow mesenchymal stromal cells by generating *Lepr-cre; Pdgfra^fl/fl^* or *Lepr-cre; Pdgfra^fl/^*^−^ mice. PDGFRa was efficiently deleted from bone marrow mesenchymal stromal cells ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}). Bone marrow cells from these mice had normal reconstitution activity when transplanted into lethally irradiated recipient mice ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}). We induced PMF by transplanting TOE virus-infected bone marrow cells into *Lepr-cre; Pdgfra^fl/fl^* and control mice. At 2--3 months after the bone marrow transplantation, HSC frequency from both *Lepr-cre; Pdgfra^fl/fl^* and control mice were similarly increased in the spleen ([Fig. 6a](#F6){ref-type="fig"}). This was accompanied by enlarged spleens with likely ongoing extramedullary haematopoiesis ([Fig. 6b--c](#F6){ref-type="fig"} and [Supplementary Fig. 5c](#SD1){ref-type="supplementary-material"}). Reticulin staining on spleen sections from *Lepr-cre; Pdgfra^fl/fl^* mice demonstrated excessive deposition of reticulin fibers to the same extent as those from control TOE mice ([Supplementary Fig. 5d](#SD1){ref-type="supplementary-material"}). These data revealed that *Lepr-cre; Pdgfra^fl/fl^* TOE mice developed many features of PMF in the spleen.

Myeloid proliferation and HSC expansion occurred similarly in *Lepr-cre; Pdgfra^fl/fl^* TOE and control TOE mice ([Fig. 6d](#F6){ref-type="fig"}). There was a significant rescue of the bone marrow cellularity in *Lepr-cre; Pdgfra^fl/fl^* mice ([Fig. 6e](#F6){ref-type="fig"}), suggesting an improvement of the bone marrow niche function. Megakaryocyte hyperplasia was similar in *Lepr-cre; Pdgfra^fl/fl^* and control TOE mice ([Supplementary Fig. 5e](#SD1){ref-type="supplementary-material"}). We then examined bone marrow fibrosis by performing reticulin staining. Consistent with our earlier observation ([Fig. 1j](#F1){ref-type="fig"}), excessive reticulin fiber deposition was observed in the bone marrow from control TOE mice ([Fig. 6f](#F6){ref-type="fig"}, upper panels and [Supplementary Fig. 5f](#SD1){ref-type="supplementary-material"}). In contrast, we did not observe reticulin staining in the bone marrow from *Lepr-cre; Pdgfra^fl/fl^* TOE mice ([Figure 6f](#F6){ref-type="fig"}, lower panels and [Supplementary Fig. 5f](#SD1){ref-type="supplementary-material"}). Consistent with the ameliorated fibrosis, flushing the bone marrow cells out of the bone from *Lepr-cre; Pdgfra^fl/fl^* TOE mice was dramatically easier compared with fibrotic control TOE bone marrow likely due to the absence of excessive fibrosis and osteosclerosis. The increased frequency of mesenchymal stromal lineage cells was suppressed to almost vector control level in *Lepr-cre; Pdgfra^fl/fl^* TOE mice ([Fig. 6g](#F6){ref-type="fig"} and [Supplementary Fig. 5g](#SD1){ref-type="supplementary-material"}). Several fibrotic genes, such as *Col1a1, Col3a1* and *Acta2*, were significantly down-regulated in *Lepr-cre; Pdgfra^fl/fl^* TOE mice ([Fig.6i](#F6){ref-type="fig"}). Thus, PDGFRa signaling in *Lepr^+^* mesenchymal stromal cells is required for bone marrow fibrosis in PMF. These data functionally show that bone marrow *Lepr^+^* mesenchymal stromal cells are the cell type responsible for fibrosis in PMF.

Imatinib effectively blocks the activity of several tyrosine kinases, including PDGFRa ^[@R42]^. We assessed whether imatinib treatment would alleviate bone marrow fibrosis. PMF was induced in TOE mice and then imatinib was administrated through chow. Imatinib effectively rescued bone marrow hypocellularity and blocked mesenchymal stromal cell expansion, fibrotic conversion, and bone marrow fibrosis ([Fig. 6e, g, h and i](#F6){ref-type="fig"}). Imatinib also effectively suppressed spleen extramedulary haematopoiesis and fibrosis, suggesting that other cell types and/or pathways may mediate PMF spleen pathogenesis ([Fig. 6a--c](#F6){ref-type="fig"} and [Supplementary Fig. 5c, h](#SD1){ref-type="supplementary-material"}). Our results suggest that targeting PDGFRa pathway in mesenchymal stromal cells may be beneficial in treating bone marrow fibrosis.

Activation of PDGFRa in *Lepr^+^* bone marrow mesenchymal stromal cells leads to their expansion and extramedullary haematopoiesis {#S9}
----------------------------------------------------------------------------------------------------------------------------------

To directly test whether activation of the PDGFRa pathway in mesenchymal stromal cells has an impact on PMF pathogenesis, we conditionally activated PDGFRa by generating *Lepr-cre; Pdgfra^D842V/+^; tdTomato* mice ([Fig. 7a](#F7){ref-type="fig"}). The *Pdgfra^D842V^* allele allows for cell-type specific activation of PDGFRa pathway under the control of its endogenous promoter ^[@R22],\ [@R23]^. By flow cytometry, bone marrow stromal cell frequency was largely unchanged in *Lepr-cre; Pdgfra^D842V/+^* mice ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}). However, by confocal microscopy, we observed foci with a significant increase of tdTomato^+^ stromal cells in the trabecular bone region of *Lepr-cre; Pdgfra^D842V/+^; tdTomato* mice ([Fig. 7b--d](#F7){ref-type="fig"}). We also observed excessive osteogenesis in the diaphysis region of these mice ([Fig. 7e--f](#F7){ref-type="fig"}). However, no excessive bone marrow fibrosis was observed ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}).

*Lepr-cre; Pdgfra^D842V/+^* mice had normal bone marrow cellularity and HSC frequency ([Fig. 7g](#F7){ref-type="fig"} and [Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}). However, these mice had increased HSC and haematopoietic progenitor frequencies in the spleens and livers ([Fig. 7h--j](#F7){ref-type="fig"} and [Supplementary Fig. 6d](#SD1){ref-type="supplementary-material"}). These results suggest that activation of PDGFRa pathway in *Lepr^+^* cells is sufficient to cause some features of PMF: mesenchymal stromal cell expansion, osteogenesis and HSC mobilization.

Discussion {#S10}
==========

Although PMF has been recognized as a haematological disease originating from abnormal HSCs, its clinical features suggest a more complex pathogenesis. The bone marrow fibrosis associated with PMF has been hypothesized as a stromal reaction to the overproliferative haematopoietic clones, but the precise identity of the reactive myofibroblasts had not previously been identified. Our fate mapping data demonstrate that *Lepr^+^* mesenchymal stromal cells are the cells of origin of myofibroblasts responsible for collagen fiber generation and deposition in PMF. The identification of these cells warrants further detailed investigation aimed at developing targeted therapies to treat bone marrow fibrosis.

In this study we observed expansion of bone marrow *Lepr^+^* mesenchymal stromal lineage cells in PMF ([Fig. 3a, c--f](#F3){ref-type="fig"} and [Supplementary Fig. 2a--d](#SD1){ref-type="supplementary-material"}). A report using *Nestin* as a marker suggests that bone marrow stromal cell number is reduced in Jak2^V617F^ mice ^[@R32]^. The authors performed *Nestin-*creER fate mapping and did not observe contribution from this lineage to myofibroblasts. Several previous studies have shown that *Nestin*-cre or *Nestin*-creER recombines in only rare bone marrow stromal cells ^[@R1],\ [@R3],\ [@R43]^. These cells are not CFU-Fs and contribute little, if any, to skeletal tissues ^[@R3],\ [@R43]^. Thus, *Nestin*-creER unlikely targets mesenchymal stromal cells. It should be noted that although low expression of a *Nestin*-GFP transgene is a marker for CFU-F, the expression of endogenous *Nestin*, or other *Nestin* transgenic lines (including *Nestin*-cre or *Nestin*-CreER) does not mark the same mesenchymal stromal cells ^[@R1],\ [@R3],\ [@R43]^. Thus, our data are consistent with the notion that *Lepr^+^* stromal cells but not *Nestin^+^*, *Nestin-*cre^+^ or *Nestin*-creER^+^ cells are the source of bone marrow myofibroblasts in PMF.

NG2^+^ cells have been reported to contain bone marrow CFU-Fs ^[@R29]^. However, a fate-mapping experiment demonstrated *Ng2*-creER^+^ cells did not contribute to PDGFRa^+^ stromal cells ^[@R29]^, suggesting these cells are unlikely the source of bone marrow fibrosis. Gli1^+^ and Gremlin-1^+^ bone marrow stromal cells also contain CFU-Fs ^[@R43],\ [@R44]^. Their contributions to bone marrow fibrosis are unknown. The contributions to bone marrow fibrosis by distinct yet overlapping mesenchymal stromal cells bearing different markers require further investigations.

Our *Lepr-cre; Pdgfra^fl/fl^* TOE mice still developed severe spleen fibrosis ([Supplementary Fig. 5d](#SD1){ref-type="supplementary-material"}). It could be that *Lepr-cre* does not target all of the spleen fibrogenic cells and/or that PDGFRa is not required for spleen fibrosis. Over-activation of PDGFRa is sufficient to drive fibrosis in diverse organs ^[@R22],\ [@R23]^. We thus favor the first possibility. Identification of the spleen fibrogenic cells will directly distinguish these possibilities. Recently, spleen *Tcf21^+^* perivascular stromal cells have been identified as an important component of the spleen niche ^[@R45]^. It will be interesting to determine the relative contributions of the *Tcf21^+^* and *Lepr^+^* cells to spleen fibrosis. Imatinib exerted more potent effects against bone marrow fibrosis and HSC mobilization than genetic deletion of *Pdgfra* from *Lepr^+^* cells ([Fig. 6](#F6){ref-type="fig"} and [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). Given that imatinib targets several tyrosine kinases including BCR-ABL, PDGFR and c-KIT, it is likely that the additional molecular and cellular targets account for the stronger effects of the drug.

*Lepr-cre; Pdgfra^D842V/+^* mice showed regional stromal cell expansion and HSC mobilization ([Fig.7](#F7){ref-type="fig"}). But the phenotypes were not as pronounced as the TOE model. This could reflect the partial activation of the PDGFRa pathway in the D842V model ^[@R22]^. However, other pathways could be co-operating in TOE to induce more prominent PMF pathology. Further elucidation of the PDGFRa and other pathways in PMF will deepen our understanding of the pathogenesis.

The modification of the bone marrow niche by abnormal haematopoietic cells is a critical contributor to many haematological diseases ^[@R4]^. Consistent with early observations ^[@R15]^, our data suggest that hyperplastic megakaryocytes are the source of PDGF and other cytokines promoting bone marrow mesenchymal stromal cell fibrosis and HSC niche dysfunction. Current therapies for PMF focused on the haematopoietic compartment by targeting the mutant haematopoietic clones. But the overall benefits are limited. Imatinib mesylate have been preliminarily explored in PMF ^[@R46],\ [@R47]^, but its clinical benefits were limited due to side effects. Our results call for additional detailed study. We propose that combined therapy against both mutant haematopoietic clone (e.g. with JAK inhibitors) and dysfunctional, fibrotic bone marrow niche (e.g. with imatinib or other PDGFRa inhibitors) with careful treatment regimen may lead to better outcome.

Methods {#S11}
=======

Mice {#S12}
----

*Lepr-cre* ^[@R48]^, *LoxptdTomato* ^[@R49]^ and *Pdgfra^fl^* ^[@R50]^ mice were obtained from the Jackson Laboratory. *Scf^gfp^, Cxcl12^DsRed^* and *Col-gfp* mice were described previously ^[@R1],\ [@R2],\ [@R34]^. *Pdgfra^D842V^* mice ^[@R22],\ [@R23]^ were kindly provided by Drs. Lorin Olson and Philippe Soriano. All mice were maintained on C57BL/6 background. Experiments were started on 8-week-old young adult mice and gender was not selected. Mice were housed in specific pathogen-free, Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC)- approved facilities at the Columbia University Medical Center. All protocols were approved by the Institute Animal Care and Use Committee of Columbia University and were under the Animal Welfare Assurance A3007-01. Two-tailed student's t-tests were used to assess statistical significance (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).

Retroviral production and infection of bone marrow cells {#S13}
--------------------------------------------------------

Mouse Tpo mRNA was cloned into pMIG retroviral vector. A DsRed version and a 'colorless' version of pMIG-Tpo were generated by replacing GFP reporter with DsRed or deleting GFP gene in pMIG, respectively. These versions of retroviral vectors allowed tracing of infected bone marrow cells in recipient mice. Retroviruses were produced by transfecting 293T cells with pMIG-Tpo or pMIG vectors along with pCL-Eco. Fluorouracil (5-FU) (150mg/kg) was injected into donor mice via I.V. route. Four to five days later, mice were euthanized and bone marrow cells were collected. DMEM with 15% heat-inactivated fetal bovine serum, 100ng/ml SCF, 10ng/ml IL-3, 10ng/ml IL-6 (from Peprotech) and 50um 2-mercaptoethanol was used to pre-stimulate 5-FU-treated bone marrow cells overnight. Two spin infections were carried out before bone marrow cells were transplanted into lethally irradiated recipient mice at 1--10 million cells /mouse.

Bone marrow transplantation {#S14}
---------------------------

Adult recipient mice were lethally irradiated by a Cesium 137 Irradiator (JL Shepherd and Associates) at 300 rad/minute with two doses of 540 rad (total 1080 rad) delivered at least 2h apart. Cells were transplanted by retro-orbital venous sinus injection of anesthetized mice. Mice were maintained on antibiotic water (Baytril 0.17g/L) for 14 days then switched to regular water. Recipient mice were periodically bled to assess the level of donor-derived blood cells (by flow cytometry), platelet (by CBC count) and serum TPO level (by ELISA).

Flow cytometry {#S15}
--------------

Bone marrow cells were isolated by flushing the long bones or by crushing the long bones with mortal and pestle in Ca^2+^ and Mg^2+^ free HBSS with 2% heat-inactivated bovine serum. Spleen cells were obtained by crushing the spleen between two glass slides. The cells were drawn by passing through a 25G needle several times and filtered with a 70μm nylon mesh. The following antibodies were used to stain HSCs: anti-CD150 (TC15-12F12.2, Biolegend, Cat\#115903 or 115911, 1:200), anti-CD48 (HM48-1, Biolegend, Cat\#103411, 1:200), anti-Sca-1 (E13-161.7, Biolegend, Cat\#122513, 1:200), anti-cKit (2B8, Biolegend, Cat\#105825, 1:200), lineage markers (anti-Ter119, Biolegend, Cat\#116205 or 116207, 1:200; anti-B220 (6B2), Biolegend, Cat\#103205 or 103207, 1:400; anti-Gr1 (8C5), Biolegend, Cat\#108405 or 108407, 1:400; anti-CD2 (RM2-5), Biolegend, Cat\#100105 or 100107, 1:200; anti-CD3 (17A2), Biolegend, Cat\#100203 or 100205, 1:200; anti-CD5 (53-7.3), Biolegend, Cat\#100605 or 100607, 1:400 and anti-CD8 (53-6.7), Biolegend, Cat\#100705 or 100707, 1:400). DAPI was used to exclude dead cells. For flow cytometric analysis of stromal cells, bone marrow was flushed using HBSS- with 2% bovine serum. Then the whole bone marrow was digested with Collagenase IV (200U/ml) and DNase I (200U/ml) at 37°C for 20 min. Samples were then stained with antibodies and analyzed by flow cytometry. Anti-CD140a (APA5), Biolegend, Cat\#135909, 1:100; anti-CD140b (APB5), Biolegend, Cat\#136009, 1:100; anti-CD45 (30-F11), Biolegend, Cat\#103111, 1:400 and anti-Ter119, Biolegend, Cat\#116211, 1:200 antibodies were used to stain mesenchymal stromal cells. For flow cytometric analysis of peripheral blood chimera levels, peripheral blood was subjected to ammonium chloride potassium red cell lysis before antibody staining. Antibodies including anti-CD45.2 (104), Biolegend, Cat\#109805, 1:400; anti-CD45.1 (A20), Biolegend, Cat\#110715, 1:200; anti-Gr1 (8C5), Biolegend, Cat\#108415, 1:400; anti-Mac-1 (M1/70), Biolegend, Cat\#101211, 1:400; anti-B220 (6B2), Biolegend, Cat\#103209, 1:400 and anti-CD3 (17A2), Biolegend, Cat\#100205, 1:200 were then added to stain cells. Samples were run on FACSAria II, LSRII or FACSCanto II flow cytometers. Data were analyzed by FACSDiva (BD) or FlowJo (Tree Star) software.

Bone sectioning and immunostaining {#S16}
----------------------------------

Freshly dissected long bones were fixed in a Formalin-based fixative at 4°C for 3 hours. Then the bones were embedded in 8% gelatin in PBS. Samples were snap frozen with liquid N~2~ and stored at −80°C. Bones were sectioned using a CryoJane system (Instrumedics). Sections were dried overnight at room temperature (RT) and stored at −80°C. Sections were re-hydrated in PBS for 5 min before immunostaining. 5% goat serum in PBS was used to block the sections. Primary antibodies were applied to the slides for 1h at RT followed by secondary antibody incubation for 30min at RT with repetitive washes in between. Slides were mounted with anti-fade prolong gold (Life Tech) and images were acquired on a Zeiss 710 confocal microscope. Rat-anti-CD41 (eBioscience, eBioMWReg30, Cat\#13-0411, 1:100) was used as primary antibody.

Reticulin staining {#S17}
------------------

Bone sections prepared as above were stained with Reticulin Stain Kit (Polysciences, Inc.) per manufacture's instruction. Images were taken on a Zeiss Axio Observer microscope.

Cell cycle analysis {#S18}
-------------------

For BrdU incorporation analysis, mice were given an intraperitoneal injection of 0.1mg BrdU in PBS per g of body weight. Then the mice were maintained on 0.5mg/ml BrdU water for 5 days before the analysis. The frequency of BrdU^+^ cells was determined by flow cytometry using an APC BrdU Flow Kit (BD Biosciences).

Quantitative reverse transcription PCR {#S19}
--------------------------------------

Cells were double-sorted directly into Trizol. Total RNA was extracted according to manufacture's instructions. Quantitative real-time PCR was run using SYBR green on a StepOne Plus (Life Tech) or a CFX Connect Real-time PCR machine (BioRad). β-actin was used to normalize the RNA content of samples. Primers used in this study were: *Scf*: OLD405: 5′-TTGTTACCTTCGCACAGTGG-3′ and OLD406: 5′-AATTCAGTGCAGGGTTCACA-3′; *Cxcl12*: OLD35: 5′-TGCATCAGTGACGGTAAACCA-3′ and OLD36: 5′- GTTGTTCTTCAGCCGTGCAA-3′; β-actin: OLD27: GCTCTTTTCCAGCCTTCCTT-3′ and OLD28: 5′-CTTCTGCATCCTGTCAGCAA-3′; *Col1a1*: OLD826: ACGGCTGCACGAGTCACAC and OLD827: GGCAGGCGGGAGGTCTT; *Col3a1*: OLD828: 5′-AGGCTGAAGGAAACAGCAAA-3′ and OLD829: 5′-TAGTCTCATTGCCTTGCGTG-3′; *Acta2*: OLD830: ACTGGGACGACATGGAAAAG and OLD831: GTTCAGTGGTGCCTCTGTCA.

Gene expression profiling and analysis {#S20}
--------------------------------------

Three independent, fresh isolated aliquots of approximately 5,000 *Cxcl12-DsRed*^+^ cells from bone marrow of from *Cxcl12^DsRed/+^* recipient mice transplanted with Tpo-overexpressing virus-infected bone marrow cells or control virus-infected bone marrow cells were flow cytometrically sorted into Trizol. Total RNA was extracted and amplified using the WT-Ovation Pico RNA Amplification system (Nugen) following manufacture's instructions. Sense strand cDNA was generated using the WT-Ovation Exon Module (Nugen). Then, cDNA was fragmented and labeled using FL-Ovation DNA Biotin Module V2 (Nugen). The labeled cDNA was hybridized to Affymetrix Mouse Gene ST 1.0 chips following the manufacture's instructions. Expression values for all probes were normalized and determined using the robust multi-array average (RMA) method via Affymetrix Expression Console. Normalized data were analyzed using NIA Array Analysis ^[@R51]^. Significantly up- or down-regulated genes (p\<0.05 and fold\>1.5) were used to performed gene ontology analysis using the Database for Annotation, Visualization and Integrated Discovery (DAVID) online tools ^[@R52],\ [@R53]^. For gene set enrichment analysis (GSEA), the complete gene expression profiles were ranked based on p values from NIA Array Analysis and used as metric. Gene sets associated with fibrogenesis and osteogenesis were obtained from [www.qiagen.com](www.qiagen.com). The analyses were performed as described ^[@R54],\ [@R55]^.

Imatinib administration {#S21}
-----------------------

Imatinib meslyate (0.5g/kg) (Biotang INC) chow was custom made by Envigo. One month after bone marrow transplantation (Tpo overexpression), mice were started on imatinib chow for 2 additional months before analysis.

Statistics and reproducibility {#S22}
------------------------------

Sample size was not based on power calculations. No animals were excluded from the analysis. The experiments were not randomized. The investigators were not blinded to allocation during experiments and result assessment. Pairwise statistical significance was evaluated by two-tailed Student's t-test. One-way ANOVA was used to analyze microarray data. All data and statistics were derived from at least three biological replicates. 293T cells were used to generate retrovirus in this study. No cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI Biosample. The cell lines were not authenticated. The cell lines were not tested for mycoplasma contamination.

Data availability {#S23}
-----------------

Microarray data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE84387. Previously published expression data that were re-analyzed here are available online ^[@R39]^. All other data supporting the findings of this study are available from the corresponding author upon reasonable request.
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![TOE mice develop clinical features of PMF\
**a.** Plasma TPO levels determined by ELISA 1 to 3 months after the bone marrow transplantation showing elevated TPO level in TOE mice compared with controls (mice transplanted with control vector virus-infected bone marrow cells) (n=16, 15 and 7 mice for control, n=15, 13 and 7 mice for TOE, at month 1-3 after transplantation, respectively).\
**b** and **c.** Peripheral blood count analysis of TOE and control mice 1 to 3 months after bone marrow transplantation (n=16, 15 and 7 mice for control, n=15, 13 and 7 mice for TOE, at month 1-3 after transplantation, respectively for **b**) (n=16, 15 and 12 mice for control, n=15, 13 and 10 mice for TOE, at month 1-3 after transplantation, respectively for **c**).\
**d.** Long bones from TOE mice were pale compared with vector controls.\
**e.** TOE mice showed enlarged spleens.\
**f.** Quantification of the spleen weight (n=13 mice for control and TOE, each).\
**g.** TOE mice bone marrow showed a significant increase of myeloid cell frequency (n=8 mice for control, n=7 mice for TOE).\
**h.** Images of bone marrow sections showing that megakaryocyte lineage cells were overproliferated in the bone marrow of TOE mice. Megakaryocytes were marked by CD41 antibody staining (in red). Nuclei were stained with DAPI (in blue).\
**i** and **j.** Reticulin staining showing extensive fibrosis in the spleen (**i**) and bone marrow (**j**) from TOE mice. Right panels of **i** and **j** are higher magnification images. TOE, Tpo-overexpressing. Con, control vector virus. All data represent mean±s.d.. Two-tailed student's t-tests were used to assess statistical significance: \*p\<0.05, \*\* p\<0.01, \*\*\* p\<0.001. Images are representative of at least 3 biological replicates.](nihms867394f1){#F1}

![HSCs overproliferate and mobilize to the spleen in TOE mice\
**a.** Representative flow cytometric plot showing the increased Lin^−^Sca1^+^cKit^+^CD150^+^CD48^−^ HSC frequency in TOE mice.\
**b.** Bone marrow HSC frequency was significantly increase in TOE mice (n=21 mice for control and n=22 mice for TOE).\
**c.** TOE mice had a significant reduction of bone marrow cellularity (n=21 mice for control and n=18 mice for TOE).\
**d.** TOE mice had an increased HSC number in the bone marrow (n=20 mice for control and n=18 mice for TOE).\
**e.** There was a significant increase of bone marrow HSC number in intermediate PMF followed by a reduction of bone marrow HSCs in advanced PMF (n=20 mice for control, n=9 mice for intermediate PMF, n=10 mice for advanced PMF).\
**f.** As the PMF developed, there was a gradually more severe reduction of bone marrow cellularity in TOE mice (n=20 mice for control, n=9 mice for intermediate PMF, n=10 mice for advanced PMF).\
**g.** Bone marrow HSCs from TOE mice incorporated significantly more BrdU in 5-day pulse experiments (n=4 mice for control and n=8 mice for TOE).\
**h.** Spleen cellularity from TOE was significantly increased (n=15 mice for control and n=12 mice for TOE).\
**i** and **j** HSC frequency and number from spleens of TOE mice were significantly increased (n=22 mice for control and n=23 mice for TOE in (**i**), n=13 mice for control and n=11 mice for TOE in (**j**)).\
**k.** Quantification of spleen and bone marrow HSC number showed a significant mobilization to the spleen in advanced stage of PMF (n=12 mice for control, n=6 mice for intermediate PMF and n=7 mice for advanced PMF). TOE, Tpo-overexpressing. Con, control vector virus. Int, intermediate stage. Adv, advanced stage. All data represent mean±sem. Two-tailed student's t-tests were used to assess statistical significance: \*p\<0.05, \*\* p\<0.01, \*\*\* p\<0.001.](nihms867394f2){#F2}

![Bone marrow mesenchymal stromal cells undergo expansion and fibrotic conversion in PMF\
**a.** Flow cytometric analysis of enzymatically dissociated bone marrow cells showing a significant increase of mesenchymal stromal cells (n=17 mice for control and n=18 mice for TOE).\
**b.** A scheme depicting the *in vivo* lineage tracing experiments.\
**c--f.** *Lepr-cre; loxptdTomato* mice were transplanted with Tpo-overexpressing virus-infected bone marrow cells (TOE) or control virus infected bone marrow cells (control). Two to three months after the transplantation, the fate of *Lepr-cre*-expressing lineage cells was followed by assessing the tdTomato^+^ cells. Confocal images showing a substantial expansion of *Lepr-cre* expressing lineage cells in TOE mice.\
**g--i.** Confocal images showing *Lepr-cre*-expressing tdTomato^+^ mesenchymal stromal cells were Col-GFP^+^ in *Lepr-cre; loxptdTomato; Col-gfp* mice under steady state.\
**j--o.** Bone marrow mesenchymal stromal cells from TOE PMF *Lepr-cre; loxptdTomato; Col-gfp* mice underwent expansion and were Col-GFP^+^. Vector controls were *Lepr-cre; loxptdTomato; Col-gfp* mice transplanted with control virus-infected bone marrow cells. TOE, Tpo-overexpressing. Con, control vector virus. Data represent mean±sem. Two-tailed student's t-tests were used to assess statistical significance: \*p\<0.05. Images are representative of at least 3 biological replicates.](nihms867394f3){#F3}

![Bone marrow mesenchymal stromal cells down-regulate key HSC maintenance factors, CXCL12 and SCF\
**a--d.** Confocal images showing *Cxcl12*-DsRed reporter expressing in the bone marrow of *Cxcl12^DsRed/+^* mice transplanted with control virus-infected bone marrow cells (**a-b**). The expression level of *Cxcl12*-DsRed reporter was dramatically down-regulated in the bone marrow of *Cxcl12^DsRed/+^* mice transplanted with Tpo-overexpressing virus-infected bone marrow cells (TOE) (**c-d**) compared with controls (**a-b**). Nuclei were stained with DAPI (blue).\
**e.** The frequency of CD45/Ter119^−^*Cxcl12*-DsRed^+^ mesenchymal stromal cells was not significantly altered in TOE mice compared with controls (n=4 mice for control and n=6 mice for TOE).\
**f--g.** The fluorescent intensity of *Cxcl12*-DsRed was significantly reduced in TOE mice compared with controls as assessed by flow cytometry (n=4 mice for control and n=6 mice for TOE).\
**h.** qPCR analysis revealed that *Cxcl12* transcripts were significantly decreased in sorted mesenchymal stromal cells from TOE mice compared with controls (n=3 mice for control and n=4 mice for TOE).\
**i--l.** The expression level of *Scf*-GFP reporter was down-regulated in TOE mice. GFP (green) shows *Scf*-GFP^+^ cells. Nuclei were stained with DAPI (blue).\
**m.** The frequency of CD45/Ter119^−^*Scf*-GFP^+^ stromal cells was not significantly altered in TOE mice (n=3 mice for control and n=4 mice for TOE).\
**n--o.** The fluorescent intensity of *Scf*-GFP was significantly reduced in TOE mice as assessed by flow cytometry (n=3 mice for control and n=4 mice for TOE).\
**p.** qPCR analysis showed *Scf* transcripts were significantly decreased in sorted mesenchymal stromal cells (n=3 mice for control and n=4 mice for TOE). TOE, Tpo-overexpressing. Con, control vector virus. All data represent mean±sem.. Two-tailed student's t-tests were used to assess statistical significance: \*p\<0.05, \*\*\*p\<0.001, NS, not significant. Images are representative of at least 3 biological replicates.](nihms867394f4){#F4}

![Mesenchymal stromal cells up-regulate fibrosis and osteogenesis genes in PMF\
**a.** Heat map showed 480 significantly up-regulated and 146 significantly down-regulated genes in freshly sorted mesenchymal stromal cells from PMF mice compared with controls identified by gene expressing profiling analysis (n=3 mice for control and TOE each).\
**b.** Gene ontology (GO) analysis showed biological processes significantly affected in mesenchymal stromal cells from PMF mice.\
**c--e.** Gene set enrichment analysis (GESA) showed significant enrichment of fibrosis genes (**c** and **d**) and osteogenesis genes (**e**) in mesenchymal stromal cells from PMF mice. NES, normalized enrichment score. FDR, false discovery rate. p, nominal p value.](nihms867394f5){#F5}

![Deletion of *Pdgfra* from mesenchymal stromal cells or administrating imatinib ameliorates bone marrow fibrosis\
**a.** *Lepr-cre; Pdgfra^fl/fl^* TOE mice had an increase of spleen HSC frequency similar to control TOE mice while imatinib suppresses HSC mobilization (n=22 mice for vector, n=10 mice for Con, n=8 mice for Mut, n=7 mice for imatinib). vector = vector in control; Con = TOE in control; Mut = TOE in *Lepr-cre; Pdgfra^fl/fl^* ; imatinib = TOE treated with imatinib.\
**b--c.** *Lepr-cre; Pdgfra^fl/fl^* TOE mice but not imatinib-treated TOE mice displayed increased spleen weight (**b**, n=18 mice for vector, n=8 mice for Con, n=7 mice for Mut, n=7 mice for imatinib) and cellularity (**c**, n=15 mice for vector, n=7 mice for Con, n=7 mice for Mut, n=7 mice for imatinib) compared with control TOE mice.\
**d.** Bone marrow from *Lepr-cre; Pdgfra^fl/fl^* TOE or imatinib-treated TOE mice had no significant change in HSC frequency, compared with control TOE mice (n=21 mice for vector, n=10 mice for Con, n=8 mice for Mut, n=7 mice for imatinib).\
**e.** *Lepr-cre; Pdgfra^fl/fl^* TOE and imatinib-treated TOE mice had significant increase of bone marrow cellularity compared with control TOE mice (n=21 mice for vector, n=10 mice for Con, n=8 mice for Mut, n=7 mice for imatinib).\
**f.** Deletion of *Pdgfra* from mesenchymal stromal cells led to blockage of reticulin deposition in the bone marrow from *Lepr-cre; Pdgfra^fl/fl^* TOE mice.\
**g.** Deletion of *Pdgfra* from *Lepr^+^* stromal cells or administration of imatinib led to suppression of the overproliferation of bone marrow CD45/Ter119^−^PDGFRb^+^ mesenchymal stromal cells in TOE mice (n=17 mice for vector, n=8 mice for Con, n=6 mice for Mut, n=7 mice for imatinib).\
**h**, Administration of imatinib led to blockage of reticulin fiber deposition in the bone marrow of TOE mice.\
**i**, Deletion of *Pdgfra* from *Lepr^+^* stromal cells or administration of imatinib suppresses fibrotic genes in bone marrow mesenchymal stromal cells (n=4 mice for vector, n=4 mice for Con, n=4 mice for Mut, n=4 mice for imatinib).\
Data represent mean±s.d.. Two-tailed student's t-tests were used to assess statistical significance: \*p\<0.05, \*\*p\<0.01, NS, not significant.](nihms867394f6){#F6}

![Activation of PDGFRa pathway in *Lepr^+^* cells leads to mesenchymal stromal cell expansion and HSC mobilization\
**a**. A scheme depicting the *in vivo* lineage tracing experiments with *Lepr-cre; Pdgfra^D842V/+^; tdTomato* mice.\
**b--c**. Confocal images showing expansion of tdTomato^+^ stromal cells in the trabecular region of bone marrow from *Lepr-cre; Pdgfra^D842V/+^; tdTomato* mice.\
**d**. Quantification of tdTomato^+^ cells on bone marrow images from trabecular region showing that tdTomato^+^ cells were significantly expanded in *Lepr-cre; Pdgfra^D842V/+^; tdTomato* mice compared with controls (n=12 representative confocal images from 3 independent mice each).\
**e--f**. Bright-field images of the diaphysis region showing excessive bone formation in *Lepr-cre; Pdgfra^D842V/+^* mice. Arrows point to bone.\
**g--h**. *Lepr-cre; Pdgfra^D842V/+^* mice had normal bone marrow HSC frequency (**g**, n=4 mice for control, n=5 mice for D842V) and spleen cellularity (**h**, n=5 mice for control, n=6 mice for D842V).\
**i--j**. *Lepr-cre; Pdgfra^D842V/+^* mice displayed increased HSC (**i**, n=5 mice for control, n=6 mice for D842V) and haematopoietic progenitor HPC (LSK) (**j**, n=5 mice for control, n=6 mice for D842V) frequencies in the spleen.\
Data represent mean±s.d.. Two-tailed student's t-tests were used to assess statistical significance: \*p\<0.05, \*\*\*p\<0.001. Images are representative of at least 3 biological replicates.](nihms867394f7){#F7}

[^1]: These authors contributed equally.
